
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
As more gene therapy applications make inroads into research and clinical practice, the development and safe manufacturing of the therapeutic products involved have demanded more from associated analytical technologies. One of the most widely used gene-therapy vectors is AAV, and key technologies for the characterization of AAVs include CE and LC-MS.







